Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) Short Interest Up 51.0% in July

Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) was the recipient of a large growth in short interest in July. As of July 31st, there was short interest totaling 16,586 shares, a growth of 51.0% from the July 15th total of 10,987 shares. Currently, 3.3% of the shares of the stock are short sold. Based on an average daily volume of 80,891 shares, the short-interest ratio is currently 0.2 days.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on ELOX. Guggenheim started coverage on Eloxx Pharmaceuticals in a research report on Monday, July 20th. They issued a “buy” rating and a $43.00 price objective on the stock. Wall Street Zen raised Eloxx Pharmaceuticals to a “hold” rating in a report on Saturday, August 1st. Lifesci Capital initiated coverage on Eloxx Pharmaceuticals in a report on Wednesday, July 22nd. They issued an “outperform” rating and a $40.00 price target on the stock. Finally, Weiss Ratings initiated coverage on Eloxx Pharmaceuticals in a research report on Friday. They set a “sell (d)” rating for the company. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $41.50.

Eloxx Pharmaceuticals Price Performance

NASDAQ:ELOX traded down $1.47 during midday trading on Tuesday, hitting $17.00. The company had a trading volume of 11,416 shares, compared to its average volume of 54,988. Eloxx Pharmaceuticals has a 52-week low of $8.20 and a 52-week high of $19.96. The stock has a fifty day simple moving average of $13.77. The firm has a market cap of $11.73 million, a P/E ratio of -1.11 and a beta of -1,863.11.

Eloxx Pharmaceuticals (NASDAQ:ELOX) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.66) earnings per share (EPS) for the quarter.

About Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company’s lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc, formerly known as Sevion Therapeutics Inc, is based in WALTHAM, United States.